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Pancreatic cancer is one of the most lethal forms of human cancer. Although progress in oncology has improved outcomes in
many forms of cancer, little progress has been made in pancreatic carcinoma and the prognosis of this malignancy remains grim.
Several molecular abnormalities often present in pancreatic cancer have been defined and include mutations in K-ras, p53, p16,
and DPC4 genes. Nuclear receptor Peroxisome Proliferator-Activated Receptor gamma (PPARγ) has a role in many carcinomas
and has been found to be overexpressed in pancreatic cancer. It plays generally a tumor suppressor role antagonizing proteins
promoting carcinogenesis such as NF-κB and TGFβ. Regulation of pathways involved in pancreatic carcinogenesis is eﬀectuated
by the Ubiquitin Proteasome System (UPS). This paper will examine PPARγ in pancreatic cancer, the regulation of this nuclear
receptor by the UPS, and their relationship to other pathways important in pancreatic carcinogenesis.
1. Introduction
Pancreatic cancer is one of the most common and most
deadly cancers with the incidence approaching mortality
[1]. Reasons contributing to this lethality are the delayed
diagnosis and the anatomic position and close relationships
of the organ that precludes complete resection in many
instances even in localized cases. Nevertheless, the majority
of patients that have been completely rejected recur. This fact
attests for the presence of occult micrometastases in early
stages and an intrinsic aggressiveness of pancreatic cancer.
Despite advancements in the molecular biology of pancreatic
cancer and discovery of key molecular lesions playing a part
in the pathogenesis such as K-ras, p53, p16, and DPC4
(Deleted in Pancreatic Cancer 4 or Smad4), this progress has
not been translated in therapeutic results. In clinical practice,
drugs used in pancreatic cancer such as gemcitabine, the
basic backbone of therapy for many years [2] and the more
recently introduced combination regimen of 5-FU, Folinic
acid, Irinotecan, and Oxaliplatin [3] are given in a non-
discriminatory way to all metastatic patients that can tolerate
them. Currently there are no clinically applicable predictive
markers of response despite a wealth of preclinical data
that pinpoint to subsets of tumors which would potentially
respond better than others [4]. Thus there is a need to further
delineate clinically such subsets.
Peroxisome Proliferator-Activated Receptor gamma
(PPARγ) is a nuclear receptor family transcription factor
that is expressed in several types of cancers among which
gastrointestinal and pancreatic cancers. It appears that the
subset of pancreatic cancers with the higher expression
of PPARγ constitutes a more aggressive group [5] and
thus research on the regulation of this transcription factor
in pancreatic cancer may present an opportunity for
defining targets and eventually better treatments. The
Ubiquitin Proteasome System (UPS) is a multi-protein
molecular machinery that has a well-established role in most
carcinogenesis processes and regulates PPARγ in multiple
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Figure 1: A schematic representation of the PPARγ molecule and its domains with their function. The molecule of PPARγ consists of
an aminoterminal domain (also called A/B domain), which is responsible for ligand-independent transcriptional regulation. The following
domain (also called domain C) contains two zinc finger-like and α-helical DNA-bindingmotifs typical of transcription factors. The C domain
interacts with DNA through a PPRE (Peroxisome Proliferator Response Element) sequence. More carboxy terminal is the hinge domain (or
D domain) which allows independent movement of the next and last domain of PPARγ molecule, domain E/F. This is the ligand-binding
domain and potentiates the ability of PPARγ to dimerize with RXRα and recruit coactivators for transcription. Several post-translational
modifications such as phosphorylation, ubiquitination, and SUMOylation modulate PPARγ activity.
ways. This regulation as it pertains to pancreatic cancer will
be discussed in this paper.
2. PPARγ Structure and Function
PPARγ is transcribed from a gene in the short arm of human
chromosome 3 (3p25) [6]. Alternative splicing of PPARγ
gene results in two isoforms. PPARγ1 isoform has a wide
tissue distribution and PPARγ2 has an expression restricted
to adipose tissue [7]. PPARγ is already expressed in the
mesodermal and endodermal layers of human embryos in
the seventh week of gestation [8] and displays comparable
to adult levels of expression in several organs during
midgestation [9]. Pancreatic beta cells are among the tissues
that physiologically express PPARγ.
The structure of PPARγ is similar to other nuclear
receptor transcription factors (Figure 1). It includes an
aminoterminal AF1 (Activation Function 1) domain that
mediates recruitment of transcription cofactors, the DNA-
binding domain (DBD) followed by a hinge region centrally,
and the ligand-binding domain (LBD) together with a
second AF2 domain in the carboxy-terminal part of the
molecule [10]. Following ligand binding, PPARγ associates
with another nuclear receptor, RXRα (Retinoid × Receptor
α), and binds to specific DNA elements called PPREs (PPAR
Response Elements), recruiting cofactors such as PGC-1
(PPARγ Coactivator-1) and the basal transcription machin-
ery for transcription initiation. PPREs consist of a direct
repeat sequence of six nucleotides divided by a single spacer
nucleotide. The 5′-part of the repeat is bound by PPARγ
and the 3′-part by RXRα. The two other members of the
PPAR family, PPARα and PPARβ/δ, use similar DNA-binding
sequences as expected by the high conservation of their DBD
[11]. The specificity of the transcription program between
the three PPAR nuclear receptors is provided by the cellular
context, the chromatin landscape and ligands and cofactors
availability [11]. In tissues where it has its highest expression,
PPARγ physiologically contributes to the regulation of diﬀer-
entiation, metabolic control, and inflammation suppression
[10]. These eﬀects are mediated by transcription of targets
genes such as lipid metabolism regulators (e.g., adipophilin
and liver fatty acid binding protein) and diﬀerentiation-
related genes (e.g., cytokeratins 18, 19 and 20 andmembers of
the Carcinoembryonic Antigen family) as well as suppression
of immune mediators (e.g., interferon γ and interleukin 2).
Both natural and synthetic ligands of PPARγ exist and
may mediate PPARγ activation. Natural PPARγ ligands
include prostaglandin D2 (PGD2) metabolite 15-deoxy-
Δ12,14-PGJ2 (15d-PGJ2), linoleic acid derivative nitrolinoleic
acid, other conjugated linoleic acid derivatives, eicosapen-
taenoic and arachidonic acids, 9-hydroxyoctadecadienoic
acid (9-HODE), 13-HODE, 15-hydroxyeicosatetraenoic
acid (15-HETE), and 13-oxooctadecadienoic acid. The
anti-diabetic class of drugs thiazolidinediones such as
pioglitazone, troglitazone, and rosiglitazone are PPARγ
agonists. The realization that PPARγ is, at least in part,
the mediator of their eﬀect has contributed in bringing the
receptor to the spotlight as a potential pharmacologic target
in diseases beyond diabetes such as cancer [12].
Several transduction cascades can aﬀect nuclear receptors
function in parallel with their ligands and PPARγ is no
exception. These cascades act through posttranslation mod-
ifications of the receptor [13]. Phosphorylation of PPARγ in
both AF1 and AF2 domains is carried out by MAPK kinases
downstream of growth factors, AMP-activated protein kinase
and PKC (Protein Kinase C) and results in transcription
PPAR Research 3
repression and in some cases subsequent ubiquitination and
proteasome degradation [14, 15]. Regulation of PPARγ by
ubiquitination will be discussed in the next section after a
brief discussion of ubiquitination machinery.
3. Ubiquitination, the Ubiquitin Proteasome
System and Regulation of PPARγ
Ubiquitination is a post-translational modification that con-
sists of attachment of the 76 aminoacids protein ubiquitin
to target proteins. This attachment is taking place through
a cascade of enzymatic reactions mediated by three types of
enzymes. The first step involves E1 (or ubiquitin-activating
enzyme) which loads an ubiquitin molecule in an ATP-
dependent manner onto a second type of enzyme, E2 (or
ubiquitin conjugating enzyme). Ubiquitin is linked to E2
through a thioester bond and is subsequently transferred to
a target protein by a third type of enzymes called ubiquitin
ligases or E3 [16]. Human genome encodes for two E1
enzymes (UBA1 and UBA6), about 30 to 40 E2 enzymes and
several hundred E3 ligases [17, 18].
E3 ligases belong to two families characterized by
specific domains, RING (Really Interesting New Gene) and
HECT (Homologous to Human Papillomavirus E6 Carboxy-
terminal domain) family. Despite diﬀering in their catalytic
mode of action, both types of E3s execute ubiquitin ligation
to the target protein [19]. There exists a third type of E3s, U-
box ligases that can be considered either a separate family
or a subfamily of RING E3 ligases due to the similarity
of U-box domain to the RING domain. RING domains
of E3 ligases constitute the interactive surface with the
ubiquitin-conjugating enzyme E2 bound to ubiquitin. Some
E3s are single polypeptides that possess both the RING E2-
binding domain and the substrate-binding domain. Other
E3s represent complexes of several distinct proteins. One
of them is the RING domain E2-binding protein. Another
protein of the complex binds the target (substrate) protein to
be ubiquitinated while often a third peptide serves as a linker
between them [19]. HECT ligases are constituted by various
aminoterminal domains while their carboxy terminus is
occupied by an HECT domain first identified and named
after E3 ligase E6-AP (Human Papillomavirus E6-Associated
Protein). HECT domain has two subdomains, one of which
binds the E2 ubiquitin-conjugating enzyme and the other
binds the substrate protein.
RING-type E3s are the most common ubiquitin ligases
and represent about 95% of human E3s, while there are less
than 30-HECT type E3s in human genome [20]. Like phos-
phorylation, ubiquitination is a reversible modification. De-
ubiquitination is carried out by deubiquitinizing enzymes
belonging to five families. The process preserves cellular
ubiquitin stocks and amends inappropriate ubiquitination
[21]. Deubiquitinases attack the isopeptide bond between
the carboxy-terminal glycine of ubiquitin and the ε-amino-
group of a lysine of another ubiquitin molecule or of a target
protein.
Ubiquitin molecule has seven lysine residues at positions
6, 11, 27, 29, 33, 48, and 63. Attachment through each of
these lysine residues as well as through the aminoterminal
ubiquitin methionine residue has been confirmed to possess
signaling potential [22, 23]. The number of ubiquitin
molecules attached encodes also for diﬀerent outcomes
[24]. A target protein may become mono-ubiquitinated
(a single ubiquitin molecule attached), multi-ubiquitinated
(one ubiquitin molecule attached in several diﬀerent lysine
residues), or polyubiquitinated (a chain of ubiquitins
attached in the same lysine residue). Lysine 48 ubiqui-
tin chains of at least four molecules are the trigger for
recognition of the target protein by the proteasome and
subsequent degradation [24]. Occasionally, lysine 6, 11, and
other lysines-mediated ubiquitin chains have been observed
to signal for target protein proteasome degradation [25].
Lysine 63-mediated ubiquitin attachment leads less often
to proteasome degradation but serves mostly as signal for
lysosome-mediated proteolysis [26]. Moreover, it serves non-
proteolytic functions including DNA repair and receptor
kinases endocytosis [26, 27]. Other processes requiring ubiq-
uitination include cell cycle progression, DNA transcription,
and DNA damage tolerance [28, 29]. The general mode of
regulation by ubiquitination is based on the recognition of an
ubiquitin molecule or chain or more complex module on the
decorated protein by another protein that bears an ubiquitin-
recognizing domain in order for the two proteins to interact
[30]. Recognition by a subunit of the proteasome is a specific
scenario that leads to subsequent degradation.
The proteasome (also called 26S proteasome) is a cylin-
drical multiprotein structure made of two substructures, a
core particle (CP or 20S proteasome) covered in one or both
sides by a regulatory particle (RP or 19S proteasome) [31].
RP is built by a lid and a base subcomplex and its role
includes the recognition of ubiquitinated proteins, unfolding
them, deubiquitination which allows ubiquitin molecules to
be recycled and delivery of the target proteins to the CP
[16]. The diﬀerent subunits of RP possess specific activities
to accomplish these functions. Three subunits of the base
subcomplex possess ubiquitin recognition domains that
allow them to recognize polyubiquitin chains. Mammalian
subunit S13 of the lid subcomplex is a de-ubiquitinase and
recycles ubiquitin from proteins that had been recognized.
The 19S base subcomplex includes six ATPases that belong to
the AAA (ATPases associated with various cellular activities)
family and are able to hydrolyze all four nucleotide triphos-
phates and to alter the conformation of substrate proteins,
preventing their aggregation before they enter the CP to be
degraded [16].
CP is made of four rings of seven member proteins
each that are stacked one on the other. The two identical
peripheral rings are named α rings (with subunits α1 to 7)
and the two similarly identical central rings are called β
rings (with subunits β1 to 7) [32]. The proteasome cleaves
target proteins through three enzymatic activities, a trypsin-
like (postbasic residues cleavage) activity, a chymotrypsin-
like (posthydrophobic residues cleavage) activity and a
post-glutamyl (caspase-like or postacidic residues cleavage)
activity, that reside in subunits β2, β5, and β1, respectively
[31]. With these activities the proteasome has the ability to
cleave almost any peptide bond-producing fragments of 4 to
14 aminoacids in length [33].
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A general role of UPS in transcription function of nuclear
receptors has emerged [34] and has been discussed for
Androgen Receptor [35]. Transcription activity of nuclear
receptors and possibly of other transcription factors is cou-
pled with their proteasome degradation. This degradation
participates in the replacement of repression complexes
by transcription activation complexes during transcription
initiation [36]. Components of the UPS are recruited in
transcribed gene promoters and eventually lead to degrada-
tion of the nuclear receptor shutting oﬀ transcription and
favoring loading of new molecules onto the promoter only
if the ligand signal persists. This permits the tight control of
hormonal signalling. As mentioned, PPARγ is a proteasome
degradation target and this degradation is coupled with
activation consistent with the above model [37]. Other
proteins of the PPARγ transcription machinery such as its
partner RXRα [38] and coactivators PGC-1α [39], SRC-1
[40], and SRC-3 [41, 42] are also proteasome substrates.
SUMOylation is a post-translational modification simi-
lar to ubiquitination that refers to the attachment of protein
SUMO (Small Ubiquitin-like Modifier) to target proteins
using also a cascade of enzymes similar to ubiquitin. A
major mode of action of SUMOylation involves modulation
of ubiquitination, most often preventing it but occasionally
facilitating subsequent ubiquitination of target proteins [43].
SUMOylation plays a role in PPARγ activity regulation.
The nuclear receptor is a substrate for this modification
which results in transcriptional repression of target genes
[44]. The transcription coactivator C/EBPβ which is a
positive regulator of expression of PPARγ is regulated
by SUMOylation, in this instance leading to subsequent
ubiquitination and proteasome degradation [45]. Another
example of SUMO-modified PPARγ cooperating proteins
is coactivator PGC-1α. SUMOylation on a specific lysine
residue of PGC-1α represses transcriptional activity by
facilitating the interaction with corepressors [46].
Ubiquitination and SUMOylation may simultaneously
or consecutively aﬀect the same proteins or diﬀerent interact-
ing proteins and constitute a post-translation modification
code that integrates multiple input signals to produce a final
PPARγ activity output [47]. In some instances, modifications
involve the proteasome and lead to degradation while in
others lead to nondegradative outcomes. It is also evident
from the above discussion that the UPS may indirectly
regulate PPARγ by aﬀecting the transcription machinery that
serves, besides itself, other transcription factors that interact
with it. Other modifications such as phosphorylation and
nitration are also participating in PPARγ regulation [48].
4. PPARγ in Pancreatic Cancer
PPARγ has been investigated inmultiple preclinical studies in
pancreatic cancer. PPARγ activation by troglitazone reduced
the proliferation of pancreatic cancer cell lines in vitro and
had an additive eﬀect with 9-cis-retinoic acid, a ligand
for RXRα [49]. Cyclin D1 mRNA and protein expression
was decreased after troglitazone treatment. Another in
vitro study of several pancreatic cell lines showed vari-
able proliferation inhibition and cell cycle arrest in G1
phase after troglitazone treatment [50]. Despite PPARγ
expression, some pancreatic cell lines were troglitazone
resistant. CDK inhibitor p21 was upregulated possibly due to
mRNA stabilization. Troglitazone treatment also promoted
diﬀerentiation of pancreatic cancer cells with duct structure
and tight junctions formation [50]. The natural PPARγ
ligand 15d-PGJ2-induced apoptosis in a pancreatic cancer
cell line with concomitant activation of MAPKs JNK, p38,
and ERK [51]. Apoptosis was dependent on MAPK p38,
as the pharmacologic inhibition of this kinase before 15d-
PGJ2 treatment prevented apoptosis induction. In contrast
pharmacologic inhibition of the ERK branch of MAPKs
had apparently no role in PPARγ-induced apoptosis after
15d-PGJ2 treatment in this cell line [51]. Troglitazone
treatment of pancreatic cancer cell lines inhibited their
invasiveness in vitro and induced a rounding of cells that was
reversible upon removal of the drug from the culture [52].
In another study a diﬀerent thiazolidinedione, ciglitazone,
and 15d-PGJ2 inhibited pancreatic cancer cell invasion [53].
This eﬀect was PPARγ dependent as it was negated by a
PPARγ antagonist or adenoviral transfection of cells with a
dominant-negative PPARγ and appeared to be at least par-
tially mediated by components of the uPA (urokinase-type
Plasminogen Activator) system. Other investigators reported
an increase of PAI-1 (Plasminogen Activator Inhibitor 1)
and a decrease in cell invasion in pancreatic cancer cell lines
treated with rosiglitazone or pioglitazone but these eﬀects
seemed to be independent of PPARγ activation because they
were observed even in cell lines that did not express the
nuclear receptor [54]. The same team of investigators showed
that rosiglitazone- or pioglitazone-induced inhibition of
anchorage-independent growth of pancreatic carcinoma
cells was PPARγ dependent [55]. PPARγ ligands also induced
a more diﬀerentiated morphology and diﬀerentiation mark-
ers Carbonic Anhydrase II (CA II) and cytokeratin 7, as
well as CDK inhibitors p21 and p27 in these cells, but
they had no apoptosis induction eﬀect [55]. Expression of
PPARγ in pancreatic cell lines needs to be accompanied by
transcriptional functionality in order to be able to mediate
inhibition eﬀect; In a study of several cancer cell lines among
which were pancreatic cell lines KMP-2 and BxPC3, only
KMP-2 could be inhibited by various thiazolidinediones
[56]. This cell line was expressing a functional PPARγ while
in BxPC3 cells, PPARγ, although robust expression was not
functional in a transactivation assay [56].
In an in vivo study in Syrian golden hamsters, piogli-
tazone feeding reduced the incidence of N-nitrosobis(2-
oxopropyl)amine (BOP-)induced pancreatic cancer [57].
These hamsters, in contrast to other rodents, have low
lipoprotein lipase (LPL) activity, develop hypertriglyc-
eridemia, and hypercholesterolemia and are particularly
sensitive to BOP carcinogenesis. Pioglitazone, in parallel
with decrease of pancreatic cancer development in these
animals, reduced the incidence of cholangiocarcinoma and
induced LPL expression [57]. In another in vivo study,
rosiglitazone treatment reduced human pancreatic xenograft
tumor size in nude mice and decreased microvessel density
evaluated by endothelial cell staining for collagen IV [58].
Pharmacologic inhibition of PPARγ by specific inhibitor
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Figure 2: The role of ubiquitination and PPARγ in the PI3K-AKT and MAPKs signaling pathways. Proteins that are regulated by
ubiquitination are depicted as yellow cycles. Examples of regulation of these pathways by PPARγ include transcriptional activation of
phosphatase PTEN and antagonism of the transcriptional activity of NF-κB.
T0070907 unexpectedly also reduced pancreatic cancer cells
migration in vitro and metastasis formation in an SCID
mouse xenograft model in vivo [59]. T0070907 treat-
ment induced membranous p120 catenin accumulation and
GTPases Cdc42 and Rac-1 inhibition, events that would be
expected to contribute to cell adhesion stabilization and
motility reduction.
Overall, these data argue for a role of PPARγ in pancreatic
cancer cell proliferation, diﬀerentiation and invasiveness.
The picture painted from available experimental evidence
speaks for a role of PPARγ activation in inducing cell
cycle arrest and a more diﬀerentiated phenotype and in
reducing cell invasiveness. Nevertheless, most data come
from in vitro studies and have limitations. One of these
limitations relates to the use of pharmacologic activators
to infer eﬀects of PPARγ activation on cellular properties.
Thiazolidinediones for example, have eﬀects that are PPARγ
independent making the evaluation of PPARγ contribution
particularly diﬃcult. Use of pancreas targeted PPARγ
knockout models in vivo or PPARγ RNA interference in
vitro instead or in addition to pharmacologic activators
would help resolving these problems. Other discrepancies
may relate to technical issues, antibodies used, and cell lines
identification. For example, a cell line used in one of the
above discussed studies [54] and reported not to express
PPARγ and thus contributing to the argument that eﬀects
seen were PPARγ independent was found to robustly express
the nuclear receptor in another study [59]. In addition,
other contradictory eﬀects may stem from diﬀerences in the
cellular environment that could alter the eﬀects of PPARγ
directly or indirectly, for example, through phosphorylation
of the receptor or availability of cofactors.
5. Molecular Lesions in Pancreatic Cancer and
Relationship with PPARγ and the UPS
Common molecular lesions in pancreatic cancer include
K-ras-activating mutations and Cyclin Dependent Kinases
(CDK) Inhibitor p16INK4A loss of function which are present
in the great majority of cases, p53-inactivating mutations
that are present in half to three-fourths of patients, and
Smad4-(also called DPC4, Deleted in Pancreatic Cancer 4)
inactivating mutations that are present in about half of
pancreatic cancers [60]. Proteins and pathways involved in
these lesions are regulated by the UPS and are interconnected
with PPARγ.
K-ras-activating mutations are an early event in
pancreatic cancer and result in the activation of several
downstream pathways among which are the Raf-MAPKs
and the PI3K-Akt both having important cancer-promoting
properties mediated by activation of procarcinogenic
eﬀectors or inhibition of tumor suppressors [61]. Activation
of PPARγ plays an antagonistic role towards K-ras-initiated
cascades. PPARγ induces phosphatase PTEN which is an
inhibitor of PI3K pathway [62, 63]. NF-κB is an example
of proteins activated by Akt kinase (Figure 2). The NF-κB
family of transcription factors is comprised of five proteins
that form homo- or heterodimers in order to perform
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Figure 3: The role of PPARγ and the UPS in the regulation of p16/CDK4/Cyclin D/Rb axis. Dysfunction of this axis promotes cell
proliferation and carcinogenesis. Cyclin D is a transcriptional repression target of PPARγ and a substrate for ubiquitination leading to
degradation by the proteasome.
their transcription function resulting in inhibition of
apoptosis and modulation of the inflammatory response.
PPARγ antagonizes the activity of NF-κB and reciprocally
NF-κB inhibits PPARγ transcription activity. Both PTEN
and NF-κB cascade are regulated by the UPS. PTEN is a
direct target of ubiquitination for proteasomal degradation
[64]. The NF-κB cascade is regulated in multiple levels by
ubiquitination that leads to proteolytic or non-proteolytic
outcomes [65]. Other components of signalling downstream
of activated K-ras such as kinases Raf [66], ERK1 and 2 [67],
and ERK3 [68], the regulatory subunit p85 of PI3K [69], and
kinase Akt [70] are subjects of regulation by ubiquitination.
CDK Inhibitor p16INK4A is a regulator of cell cycle
and functions by inhibiting the CDK4/Cyclin D complex
leading to the release of Rb from the negative regulation
by the complex and cell cycle arrest at the G1/S transition
[71]. Its inactivation in the great majority of pancreatic
cancers promotes cell proliferation and synergizes with K-
ras mutations to promote pancreatic carcinogenesis [72].
Dysfunctioning p16INK4A/CDK4/Cyclin D/Rb axis may still
be regulated by PPARγ which is a transcriptional repressor
of Cyclin D. Furthermore, this Cyclin is regulated by the UPS
by being a target protein for ubiquitination and degradation
[73] (Figure 3). In addition, PPARγ interacts with Rb protein
and the PPARγ/Rb complex recruits histone deacetylase 3
(HDAC3) and causes cell cycle arrest at the G1 phase of the
cell cycle in mouse embryo fibroblasts [74].
Tumor suppressor p53 mediates PPARγ induction of
apoptosis in various cell types and as a result its inactivation
in pancreatic cancer may interfere with the ability of PPARγ
to induce apoptosis [75, 76]. However, in other cell types
PPARγ-induced apoptosis may be p53 independent [77]. The
eﬀect of p53 inactivation on the ability of PPARγ to mediate
apoptosis in pancreatic cancer has not been specifically
studied. Nevertheless, the fact that the nuclear receptor
retains the ability to promote apoptosis in pancreatic cells,
which are often p53 mutant, argues for at least a partially
p53-independent ability of PPARγ to induce apoptosis. p53
is a short-lived protein and its stability is normally regulated
by proteasome degradation after ubiquitination. Mutant p53
is not recognized by the ubiquitination machinery and, as
a result, is stabilized and can act as a dominant negative
regulator of the wild type protein [78].
Smad4 mutations are common in pancreatic cancer and
are associated with poor prognosis compared with patients
that harbor a wild-type Smad4 in their tumors [79]. Smad4
is part of the TGFβ signal transduction cascade. Ligation of
TGFβ to its cell surface receptors TβRI and TβRII activates
proteins Smad2 and Smad3 which form dimers with Smad4
and act as transcription factors [80]. PPARγ is a transcription
suppression target of the TGFβ signaling pathway in diverse
tissues [81, 82] and deregulation of this pathway as a result
of Smad4 mutations may lead to PPARγ upregulation in
pancreatic carcinomas (Figure 4). This reverse association
may also explain the poor prognosis associated not only with
Smad4 mutations [79] but also with PPARγ upregulation
[5]. A reciprocal regulation whence PPARγ agonists inhibit
TGFβ signaling is evident in some experimental systems
but probably represents a PPARγ-independent eﬀect of
these ligands [83, 84]. The UPS controls TGFβ signaling
by degradation of most of its protein components. HECT
E3 ligases of the Nedd4 (Neural precursor cells Expressed
Developmentally Downregulated 4) family including Nedd4-
2, Smurf1 and 2, WWP1, and Itch/AIP4 participate in TGFβ
signalling regulation [85, 86]. In addition, receptor endocy-
tosis after TGFβ ligation, which leads to either degradation
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Figure 4: The TGFβ pathway and regulations by ubiquitination and PPARγ. Its deregulation by Smad4 mutations may lead to
PPARγ upregulation in pancreatic carcinomas. Several components of TGFβ pathway are targets of ubiquitination with degradative and
nondegradative outcomes.
in the lysosome or recycling to the cell surface, is UPS
regulated [87]. Other ubiquitination modifications of TGFβ
cascade proteins with a nondegradational outcome have been
identified [88]. Pancreatic cancer-associated Smad4 mutant
proteins are more prone to ubiquitination and subsequent
proteasome degradation than the wild-type Smad4 [89].
It is concluded from the above discussion that all major
pathways aﬀected in pancreatic cancer are interconnected
with PPARγ and are regulated in multiple nodes by the UPS.
6. Inflammation and Fibrosis in Pancreatic
Cancer: Role of PPARγ and the UPS
There exists a relationship between chronic pancreatitis and
pancreatic cancer [1]. Obesity, a condition of low-grade
inflammation is also associated with pancreatic cancer [90].
Chronic inflammation leads to fibrosis (also referred to
as desmoplasia or desmoplastic reaction) and to a change
in the cellular microenvironment that promotes carcino-
genesis. Transcription factor NF-κB is a major regulator
of inflammation and is regulated by the UPS in multiple
levels [65]. A major regulating point in the NF-κB pathway
involves phosphorylation of inhibitor of NF-κB, IκB which
is then ubiquitinated and degraded in the proteasome. In
addition, NF-κB lies downstream of activated K-ras and as
a result, it may be activated secondary to diverse signals in
pancreatic cancer. These signals not only favor carcinogenesis
but also perpetuate the inflammatory environment [72, 91].
NF-κB signaling results in phosphorylation of histone H3
in the promoter of Notch target gene and transcriptional
repressor Hes (Hairy and Enhancer of Split) and through
this modification cooperates with Notch in upregulation of
Hes [92]. Hes suppresses, among other genes, transcription
of PPARγ, neutralizing an anti-inflammatory signal in
pancreatic cancer and thus promoting an inflammatory
microenvironment. There exists a reciprocal antagonism of
PPARγ towards NF-κB that may be relevant in pancreatic
carcinoma cases with increased PPARγ expression [93]
(Figure 5). Several mechanisms are proposed to contribute
in PPARγ antagonism to NF-κB. First, PPARγ, as already
mentioned in the previous section, induces PTEN in pancre-
atic cancer cells which dephosphorylates and inhibits kinase
PI3K blocking the signal from activated K-ras to NF-κB
[62]. This may be an important mechanism with therapeutic
implications because, in addition to K-ras mutations, PTEN
downregulation is frequent in pancreatic cell lines and
tumor specimens [94, 95]. A second mechanism relates to
a direct ligand-dependent transrepression of NF-κB target
genes by PPARγ through recruitment of co-repressors [96].
A third mechanism involves the downregulation by PPARγ
of cytokines and STAT transcription factors that are NF-κB
activators or eﬀectors [97].
Fibrosis is a frequent feature of pancreatic cancer and
has been proposed to be a cause of drug resistance creating
a protective barrier for the neoplastic cells that chemother-
apeutics cannot penetrate at least at concentrations to be
eﬀective [98]. TGFβ signaling is a central player in fibrosis
and in carcinogenesis. In pancreatic cancer, there is an
imbalance between the canonical Smad transduction which
is debilitated due to Smad4 mutations and the noncanonical
MAPK pathway which, in addition to the nonaﬀected
transduction from TGFβ receptors, receives the input from
the activated K-ras [99]. This imbalance promotes TGFβ-
associated fibrosis and carcinogenesis. PTEN induction by
PPARγ appears to be important for an antagonistic eﬀect
of the nuclear receptor towards TGFβ signaling, similar to
its role in PPARγ antagonism towards NF-κB (Figure 6).
In this instance kinase p70 Ribosomal S6 Kinase-1 is
inhibited downstream of PTEN and results in inhibition
of transcription factor Zf9, a TGFβ1 gene inducer [100].
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Figure 5: A schematic representation of the role of PPARγ and UPS in inflammation. UPS regulates NF-κB (here subunits p65 and p50 are
depicted) in multiple points, one of which is degradation of inhibitor IκB. Activated NF-κB cooperates with Notch in the induction of Hes.
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Figure 6: The role of PPARγ in the pathogenesis of fibrosis. PTEN induction by PPARγ inhibits the PI3K/Akt pathway downregulating
transcription factor Zf9, an inducer of TGFβ. Resulting decrease of TGFβ signaling leads to a decrease of collagen production. UPS regulates
all these pathways (not shown).
Reciprocally MAPK cascade activation antagonizes PPARγ
by promoting its nuclear exclusion [101].
Pancreatic stellate cells, cells morphologically and bio-
chemically similar to hepatic stellate (Ito) cells [102],
are principal eﬀectors in inflammation-associated pancre-
atic fibrosis. Physiologically, these cells are quiescent but
after activation, for example, in pancreatitis, they produce
increased collagen and other matrix proteins leading to
fibrosis [103]. Studies in animal models have shown that
stellate cells promote tumor formation when coadministered
with pancreatic cancer cells [104] suggesting an experimental
explanation for the link between inflammation, fibrosis, and
cancer. PPARγ activation decreased collagen synthesis of
pancreatic stellate cells in vitro and enhanced their diﬀeren-
tiation to adipocytes with production of lipid metabolism-
related proteins [105]. A decrease in their proliferation was
also observed.
Fibrosis may also be a result of EMT (Epithelial to Mes-
enchymal Transition), a program of cancer cells that
allows the acquisition of fibroblast-like morphology and
properties by epithelial cells and promotes detachment
from epithelial membranes, motility, and metastasis [106].
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It is conceivable that cells having undergone EMT and
acquired fibroblast properties contribute to the production
of fibrotic matrix and promote drug resistance [107]. In
addition, this resistance is an innate property of EMT of
epithelial cells and relates to common pathways mediating
EMT and the acquisition of a stem cell phenotype that
accompanies it [108]. Moreover activated pancreatic stellate
cells promote the stem cell phenotype of pancreatic cancer
cells, expression of resistance proteins such as ABCG2, EMT
in vitro, and tumorigenicity in vivo [109, 110]. The UPS is
an important modulator of EMT by regulating both signal
transduction pathways and transcription factors mediating
it [111, 112].
PPARγ as an antagonist of TGFβ signaling, a promoter of
EMT, is expected to inhibit this process. Indeed, this has been
confirmed in a study of lung cancer cells [113]. Nevertheless,
another study using mouse and rat intestinal epithelial cells
concluded that PPARγ activation promotes EMT [114]. This
eﬀect was dependent on activation of kinases ERK1 and
ERK2 of the MAPK cascade. ERK activation was a result of
Rho GTPase activity in this study, a molecular event that
was also observed in a study of PPARγ inhibitor T0070907
discussed in a previous section which, in contrast, has found
migration inhibition by inhibiting PPARγ [59]. Discrepant
eﬀects of PPARγ on EMT replicate discrepancies that have
been seen with diﬀerent mouse models of colorectal car-
cinogenesis with some models showing cancer protection by
PPARγ activation while others displaying cancer-promoting
eﬀects [115] and may be explained by diﬀerences in cellular
context, expressed by quantitative and qualitative diﬀerences
in activity status of other parallel pathways such as the TGFβ,
the MEK/ERK, and the PI3K/Akt pathways.
Despite these issues, the bulk of the data supporting a
role of PPARγ in suppression of inflammation and fibrosis
also suggests a beneficial role of the nuclear receptor in
carcinogenesis suppression.
7. Therapeutic Perspectives
Given the above discussed antagonism of PPARγ activation
against several carcinogenesis promoting pathways but also
its antagonism to inflammation and fibrosis predisposing
to cancer, PPARγ is a rational pharmacologic target in
pancreatic cancer. Such a target has the additional advantage
that there already exist drugs in clinical use, the thiazo-
lidinediones, with known safety profile [12]. Although safety
concerns related to severe hepatotoxicity have led to the
withdrawal of troglitazone from the market, this toxicity is
not a class eﬀect [116]. More recently, an increased risk of
bladder cancer has been noticed in diabetic patients taking
pioglitazone but not those treated with rosiglitazone [117]
again arguing against a class eﬀect but adding to the safety
concerns with thiazolidinediones.
There are ample preclinical data supporting the eﬀec-
tiveness of thiazolidinediones in pancreatic cancer, as dis-
cussed in a previous section. In addition, combination
of thiazolidinediones with commonly used chemotherapy
drugs such as gemcitabine and platinum resulted in syner-
gistic antineoplastic eﬀects [118, 119] encouraging moving
forward to clinical trials. Nevertheless, initial clinical trials of
thiazolidinediones in various malignancies as monotherapy
have not produced significant benefit [120].
The role of UPS in most carcinogenesis-related processes
and the clinical success of its inhibition by the boronic acid
derivative bortezomib in multiple myeloma have confirmed
UPS as a valid anti-neoplastic target [121]. Despite this
success of bortezomib in myeloma and subtypes of Non-
Hodgkin lymphoma, results in solid tumors were generally
disappointing. In pancreatic cancer, despite encouraging
preclinical data [122], no benefit was observed in a phase
I study investigating the combination of bortezomib with
gemcitabine [123].
How can one reconcile these disappointing clinical
results with drugs modulating apparently valid targets that
have been extensively investigated preclinically? Both PPARγ
and the proteasome, despite representing single targets,
are involved in multiple cellular processes: the proteasome
by degrading hundreds of cellular proteins and PPARγ
by transcribing dozens of target genes, suppressing others
and interacting with several parallel signals. Thus, the final
output of both PPARγ activation and proteasome inhibition
in a given neoplastic cell is highly context-dependent. As
a result, there is a need for predictive markers to help
delineate a priori patients that have the greatest probability
of response. This quest of predictive markers is indeed a
cornerstone of modern oncology and a prerequisite for the
development of targeted treatments. Concerning proteasome
inhibition, such markers were not necessary in myeloma
possibly because myeloma cells have functions such as
antibody production after recombination that makes them
sensitive to this inhibition in the majority of cases. More
specific pharmacologic interventions could also be a solution
that could be attained by inhibition of specific ubiquiti-
nation enzymes instead of the proteasome. Such inhibitors
are already in development [124, 125]. Regarding PPARγ,
current activators, as mentioned, have safety concerns. In
addition they have oﬀ-target eﬀects that have been a hurdle
for the preclinical study of PPARγ activation but may also
be at least partially responsible for the encountered adverse
events. Thus, development of more specific activators is
highly desirable. Given the importance of both PPARγ
and the UPS in regulating pancreatic cancer cells and
their interrelation as outlined in this paper, it is worth
investigating the existence of possible subsets of pancreatic
cancers that would be sensitive to the combination of specific
PPARγ activators with UPS inhibitors.
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